Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena Escuin

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancer Immunology Research|May 6, 2014
Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and functionDeborah J L Wong, Amol Rao, Earl Avramis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 23, 2018
Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy ProductsTheodore S Nowicki, Helena Escuin-Ordinas, Earl Avramis, et al.
Plos One|June 23, 2021
Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effectsHelena Escuin-Ordinas, Yining Liu, Lu Sun, et al.
Molecular Oncology|December 19, 2013
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitorsHelena Escuin-Ordinas, Mohammad Atefi, Yong Fu, et al.
Journal for Immunotherapy of Cancer|January 11, 2023
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor controlMaria E Rodriguez-Ruiz, Irantzu Serrano-Mendioroz, Eneko Garate-Soraluze, et al.
Cell Reports|May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Nature Communications|August 2, 2016
Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitorsHelena Escuin-Ordinas, Shuoran Li, Michael W Xie, et al.
Nature|June 8, 2022
Potentiating adoptive cell therapy using synthetic IL-9 receptorsAnusha Kalbasi, Mikko Siurala, Leon L Su, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancer Immunology Research|May 6, 2014
Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and functionDeborah J L Wong, Amol Rao, Earl Avramis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 23, 2018
Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy ProductsTheodore S Nowicki, Helena Escuin-Ordinas, Earl Avramis, et al.
Plos One|June 23, 2021
Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effectsHelena Escuin-Ordinas, Yining Liu, Lu Sun, et al.
Molecular Oncology|December 19, 2013
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitorsHelena Escuin-Ordinas, Mohammad Atefi, Yong Fu, et al.
Journal for Immunotherapy of Cancer|January 11, 2023
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor controlMaria E Rodriguez-Ruiz, Irantzu Serrano-Mendioroz, Eneko Garate-Soraluze, et al.
Cell Reports|May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Nature Communications|August 2, 2016
Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitorsHelena Escuin-Ordinas, Shuoran Li, Michael W Xie, et al.
Nature|June 8, 2022
Potentiating adoptive cell therapy using synthetic IL-9 receptorsAnusha Kalbasi, Mikko Siurala, Leon L Su, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
Pageof 3